Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cogent Biosciences (COGT) EBITDA Margin (2017 - 2020)

Historic EBITDA Margin for Cogent Biosciences (COGT) over the last 4 years, with Q3 2020 value amounting to 16020.19%.

  • Cogent Biosciences' EBITDA Margin fell 148512700.0% to 16020.19% in Q3 2020 from the same period last year, while for Dec 2020 it was 950.43%, marking a year-over-year decrease of 8089900.0%. This contributed to the annual value of 10745.56% for FY2025, which is N/A changed from last year.
  • According to the latest figures from Q3 2020, Cogent Biosciences' EBITDA Margin is 16020.19%, which was down 148512700.0% from 1400.19% recorded in Q2 2020.
  • In the past 5 years, Cogent Biosciences' EBITDA Margin registered a high of 15.02% during Q4 2019, and its lowest value of 16020.19% during Q3 2020.
  • For the 4-year period, Cogent Biosciences' EBITDA Margin averaged around 1478.0%, with its median value being 325.73% (2017).
  • The largest annual percentage gain for Cogent Biosciences' EBITDA Margin in the last 5 years was 2959300bps (2020), contrasted with its biggest fall of -148512700bps (2020).
  • Cogent Biosciences' EBITDA Margin (Quarter) stood at 314.74% in 2017, then grew by 28bps to 225.86% in 2018, then surged by 107bps to 15.02% in 2019, then plummeted by -106725bps to 16020.19% in 2020.
  • Its EBITDA Margin was 16020.19% in Q3 2020, compared to 1400.19% in Q2 2020 and 86.67% in Q1 2020.